Human pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) after repeated doses taken 2 h apart

被引：0
作者：
A. M. Peiró
M. Farré
P. N. Roset
M. Carbó
M. Pujadas
M. Torrens
J. Camí
R. de la Torre
机构：
[1] IMIM-Hospital del Mar Medical Research Institute,Human Pharmacology and Clinical Neurosciences Research Group, Neurosciences Research Programme
[2] Universitat Autònoma de Barcelona (UDIMAS-UAB),CIBER de Fisiopatología de la Obesidad y Nutrición (CB06/03)
[3] Universitat Pompeu Fabra (CEXS-UPF),undefined
[4] Addiction Unit - INAD,undefined
[5] Doctor Aiguader 88,undefined
[6] CIBEROBN,undefined
来源：
Psychopharmacology | 2013年 / 225卷
关键词：
MDMA; Ecstasy; Repeated dose; Humans; Metabolic inhibition; Pharmacologic effects; Pharmacokinetics; CYP2D6;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：883 / 893
页数：10
相关论文
共 50 条
[41]   Surviving life-threatening MDMA (3,4-methylenedioxymethamphetamine, ecstasy) toxicity caused by ritonavir (RTV) [J].
Esther Papaseit ;
Antonia Vázquez ;
Clara Pérez-Mañá ;
Mitona Pujadas ;
Rafael de la Torre ;
Magí Farré ;
Joan Nolla .
Intensive Care Medicine, 2012, 38 :1239-1240
[42]   Depression, impulsiveness, sleep, and memory in past and present polydrug users of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) [J].
Lynn Taurah ;
Chris Chandler ;
Geoff Sanders .
Psychopharmacology, 2014, 231 :737-751
[43]   Depression, impulsiveness, sleep, and memory in past and present polydrug users of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) [J].
Taurah, Lynn ;
Chandler, Chris ;
Sanders, Geoff .
PSYCHOPHARMACOLOGY, 2014, 231 (04) :737-751
[44]   Changes in CYP1A2 Activity in Humans after 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy) Administration Using Caffeine as a Probe Drug [J].
Yubero-Lahoz, Samanta ;
Pardo, Ricardo ;
Farre, Magi ;
Mathuna, Brian O. ;
Torrens, Marta ;
Mustata, Cristina ;
Perez-Mana, Clara ;
Langohr, Klaus ;
Carbo, Marcel-li ;
de la Torre, Rafael .
DRUG METABOLISM AND PHARMACOKINETICS, 2012, 27 (06) :605-613
[45]   Level of use of 3,4-methylenedioxymethamphetamine (MDMA or Ecstasy) in humans correlates with EEG power and coherence [J].
R. I. Dafters ;
Frances Duffy ;
Patrick J. O’Donnell ;
Caroline Bouquet .
Psychopharmacology, 1999, 145 :82-90
[46]   The entactogen 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) as a treatment aid in psychotherapy and its safety concerns [J].
Baldo, Brian A. .
ARCHIVES OF TOXICOLOGY, 2024, 98 (08) :2409-2427
[47]   3,4-Methylenedioxymethamphetamine (MDMA, "ecstasy") and its stereoisomers as reinforcers in rhesus monkeys: serotonergic involvement [J].
Fantegrossi, WE ;
Ullrich, T ;
Rice, KC ;
Woods, JH ;
Winger, G .
PSYCHOPHARMACOLOGY, 2002, 161 (04) :356-364
[48]   A study of the mechanisms involved in the neurotoxic action of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') on dopamine neurones in mouse brain [J].
Colado, MI ;
Camarero, J ;
Meehan, AO ;
Sanchez, V ;
Esteban, B ;
Elliott, JM ;
Green, AR .
BRITISH JOURNAL OF PHARMACOLOGY, 2001, 134 (08) :1711-1723
[49]   Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) and its congeners [J].
G. Huether ;
D. Zhou ;
E. Rüther .
Journal of Neural Transmission, 1997, 104 :771-794
[50]   Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4-methylenedioxymethamphetamine (MDMA, ''ecstasy'') and its congeners [J].
Huether, G ;
Zhou, D ;
Ruther, E .
JOURNAL OF NEURAL TRANSMISSION, 1997, 104 (8-9) :771-794
12345